NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development.
This study investigated how dysregulation of the NLRP3 inflammasome in melanocytes contributes to vitiligo pathogenesis. Using skin samples from vitiligo patients and a melanoma-Treg-induced vitiligo mouse model, the researchers found that NLRP3 expression is significantly elevated in vitiligo melanocytes. Mechanistically, they identified that decreased expression of the E3 ubiquitin ligase β-TrCP1 in vitiligo melanocytes reduces K27-linked ubiquitination of NLRP3, weakening its interaction with the autophagy receptor NDP52. This disrupts selective autophagic clearance of NLRP3, allowing it to hyperactivate inflammatory and pyroptotic pathways—including GSDMD pore formation and IL-1β release—ultimately destroying melanocytes. Genetic knockout of NLRP3 in mice alleviated vitiligo progression. As a potential therapeutic approach, the authors developed lysine-proline-valine (KPV)-modified deformable liposomes carrying Nlrp3 shRNA, which achieved melanocyte-targeted NLRP3 knockdown and reduced vitiligo development in mice. Key limitations include reliance primarily on a mouse model, limited human mechanistic validation, and the therapeutic intervention being tested only in animals, leaving clinical translation unestablished.
Why this grade: Although human vitiligo patient samples were used to confirm NLRP3 upregulation, the mechanistic investigations and all therapeutic interventions were conducted in mouse models and cell-based systems, limiting direct human evidence.
NLRP3 functions as a critical intracellular danger sensor for inflammasome activation, playing a crucial role in autoimmune diseases. Vitiligo progression has been linked to NLRP3, yet its specific involvement in melanocytes of vitiligo remains poorly understood. In this study, we demonstrate that NLRP3 expression is significantly upregulated in the melanocytes of vitiligo patients and melanoma-Treg-induced vitiligo mouse model. Genetic knockout of NLRP3 effectively alleviates vitiligo progression in these mice. Our mechanistic investigations reveal that the downregulation of the E3 ligase β-TrCP1 in vitiligo melanocytes decreases K27-linked ubiquitination levels of NLRP3, which in turn weakens its interaction with the autophagy receptor NDP52. This disruption impairs the selective autophagic degradation of NLRP3, leading to hyperactivation of inflammation and pyroptosis in melanocytes, thereby accelerating vitiligo pathogenesis. Notably, melanocyte-specific knockdown of NLRP3 using lysine-proline-valine (KPV)-modified deformable liposomes (KPV-Lipos) carrying Nlrp3 shRNA significantly alleviates vitiligo development. This study elucidates the mechanism by which autophagy dysfunction mediated excessive NLRP3 inflammasome activation in melanocytes contributes to vitiligo pathogenesis, highlighting potential therapeutic strategies targeting these pathways for the treatment of vitiligo and other pigment-related skin diseases. Overview of disrupted NLRP3 autophagic degradation in vitiligo melanocytes. In healthy melanocytes, NLRP3 expression is upregulated when subjected to oxidative stress, along with an increase in the E3 ligase β-TrCP1, which enhances the K27-linked ubiquitination of NLRP3 and further strengthens its binding to the autophagy receptor protein NDP52, thus effectively suppressing the excessive inflammatory response. Whereas in the melanocytes of vitiligo patients, decreased expression of β-TrCP1 leads to downregulation of K27-linked ubiquitination in NLRP3, thus inhibiting its autophagic degradation. The persistent activation of NLRP3 in vitiligo melanocytes promotes the cleavage of pro-IL-1β and GSDMD. GSDMD-N subsequently forms pores on the cell membrane, which causes the release of IL-1β and results in melanocyte pyroptosis. In our study, we utilize KPV-Lipos with Nlrp3 shRNA to precisely knockdown NLRP3 expression in melanocytes and effectively alleviate vitiligo development, which provide a potentially promising strategy for the treatment of vitiligo. MC, melanocytes.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.